Company Overview and News

0
MF investors fret over changes in scheme names

2018-06-11 thehindubusinessline
Suresh P Iyengar Sanjay Swaroop, a conservative mutual fund investor from Odisha, was surprised when the words ‘credit risk’ suddenly cropped up in two of the mutual fund schemes he had invested in, thinking they were as safe as recurring deposits at banks.
HDFCNIFETF 539516

0
HDFC Mutual Fund seeks SEBI approval for ultra short term fund

2018-05-31 moneycontrol
HDFC Mutual Fund has sought the Securities and Exchange Board of India's approval for its HDFC Ultra Short Term Fund, according to the draft offer document available on the regulator's website.
HDFCNIFETF 539516

0
HDFC Mutual Fund buys stake worth Rs71 crore in Vardhman Textiles

2018-05-29 livemint
New Delhi:HDFC Mutual Fund on Tuesday picked up 1% stake in Vardhman Textiles for over Rs71 crore through an open market transaction.
VTL HDFCNIFETF 502986 539516

0
HDFC MF to suspend subscriptions in HDFC Long Term Advantage Fund

2018-04-30 moneycontrol
HDFC Mutual Fund will discontinue subscriptions and systematic investments in HDFC Long Term Advantage Fund with effect from May 16, the fund house said in an addendum.
HDFCNIFETF 539516

17
MF Weekly Wrap: Fund managers cautious on ICICI Bank, Axis Bank over leadership uncertainty

2018-04-14 moneycontrol
In the week gone by, ICICI Bank and Axis Bank remained the buzz word with the controversies surrounding the leaders of these banks.
AXBKY HDFCNIFETF AXBA ICICIBANK AXB AXISBANK 532174 IBN 539516 532215

0
MFs: Retail investors make their mark

2018-04-13 thehindubusinessline
Retail investors are holding the fort at mutual funds at a time when large corporates and high networth investors explore other investment options.
HDFCNIFETF 539516

0
HDFC Mutual Fund to change type, allocation of HDFC Gold ETF from May 16

2018-04-09 moneycontrol
HDFC Mutual Fund will change the type and asset allocation of HDFC Gold Exchange Traded Fund with effect from May 16, the fund house stated in an addendum.
HDFCNIFETF 539516

0
Assets Under Management of mutual funds swell 26% to ₹23 lakh-crore in FY18

2018-04-05 thehindubusinessline
Suresh P Iyengar Thanks to the ‘Mutual Funds Sahi Hain’ campaign, the industry seems to have hit the right growth trajectory even as uncertainty looms large on the growth prospects of the economy and corporate earnings.
HDFCNIFETF 500710 AKZOINDIA 539516

0
HDFC MF to start HDFC Flex systemic investment plan from April 3

2018-03-27 moneycontrol
HDFC Mutual Fund will introduce HDFC Flex systematic investment plan for investments under the growth option plan of open-ended equity and balanced funds, with effect from April 3, the mutual fund house said in an addendum.
HDFCNIFETF 539516

0
HDFC Mutual FUND buys 50,000 shares of Shaily Engineering Plastics

2018-03-27 moneycontrol
On March 26, 2018 HDFC Mutual FUND-Small Cap Fund bought 50,000 shares of Shaily Engineering Plastics at Rs 1,150 on the BSE.
HDFCNIFETF 501423 SHAILY 539516

0
HDFC Mutual Fund buys 50,000 shares of Shaily Engineering

2018-03-23 moneycontrol
On March 22, 2018 HDFC Mutual Fund Small Cap Fund bought 50,000 shares of Shaily Engineering Plastics at RS 1,140 on the BSE.
HDFCNIFETF 501423 SHAILY 539516

14
IDFC may put its AMC biz on sale: Here#39;s what makes it an attractive buy

2018-03-22 moneycontrol
IDFC Asset Management Company is up for sale, and may soon be acquired by another large mutual fund player or a company as the AMC’s parent, IDFC is looking to exit the AMC business.
STAN 532938 INDUSINDBK CAPF 539516 539437 HDFCNIFETF 532187 IDFCBANK 580001 STAB STAN STAC 2888 SCBFF

0
JP Morgan Funds buys 4 lakh shares of TeamLease Services

2018-03-17 moneycontrol
On March 16, 2018 HDFC Mutual Fund - Prudence sold 3,80,121 shares of TeamLease Services at Rs 2,050 on the NSE.
HDFCNIFETF 539516

0
HDFC to offload 4% in asset management arm via IPO

2018-03-13 thehindubusinessline
Our Bureau Housing Development Finance Corporation, a mortgage lending firm, has decided to offload a little over 4 per cent of its holding in its subsidiary HDFC Asset Management Company through an initial public offering.
HDFCNIFETF 539516

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...